[go: up one dir, main page]

MX2017009764A - Agentes mucolíticos de monotiol novedosos. - Google Patents

Agentes mucolíticos de monotiol novedosos.

Info

Publication number
MX2017009764A
MX2017009764A MX2017009764A MX2017009764A MX2017009764A MX 2017009764 A MX2017009764 A MX 2017009764A MX 2017009764 A MX2017009764 A MX 2017009764A MX 2017009764 A MX2017009764 A MX 2017009764A MX 2017009764 A MX2017009764 A MX 2017009764A
Authority
MX
Mexico
Prior art keywords
novel
mucolytic agents
formulas
monothiol
monothiol mucolytic
Prior art date
Application number
MX2017009764A
Other languages
English (en)
Other versions
MX387071B (es
Inventor
R Thelin William
Ross Johnson Michael
Original Assignee
Parion Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parion Sciences Inc filed Critical Parion Sciences Inc
Publication of MX2017009764A publication Critical patent/MX2017009764A/es
Publication of MX387071B publication Critical patent/MX387071B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/29—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/16—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/28—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporciona un agente mucolítico representado por las fórmulas (Ia)-(Id): [ver fórmulas (Ia)-(Id)] donde las variables estructurales R1, R2, R5 y R6 15 son como se definen en la presente. También se proporcionan una variedad de métodos de tratamiento los cuales toman ventaja de las propiedades mucolíticas de los compuestos representados por las fórmulas (Ia)-(Id).
MX2017009764A 2015-01-30 2016-01-28 Agentes mucolíticos de monotiol novedosos MX387071B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562109999P 2015-01-30 2015-01-30
PCT/US2016/015353 WO2016123335A1 (en) 2015-01-30 2016-01-28 Novel monothiol mucolytic agents

Publications (2)

Publication Number Publication Date
MX2017009764A true MX2017009764A (es) 2018-03-28
MX387071B MX387071B (es) 2025-03-19

Family

ID=56544326

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009764A MX387071B (es) 2015-01-30 2016-01-28 Agentes mucolíticos de monotiol novedosos

Country Status (13)

Country Link
US (2) US10106551B2 (es)
EP (1) EP3250548A4 (es)
JP (2) JP6826038B2 (es)
KR (1) KR20170108088A (es)
CN (2) CN112321472A (es)
AU (1) AU2016211440B2 (es)
BR (1) BR112017016067A2 (es)
CA (1) CA2974210A1 (es)
IL (1) IL253501B (es)
MX (1) MX387071B (es)
SG (1) SG11201705790SA (es)
WO (1) WO2016123335A1 (es)
ZA (1) ZA201705122B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105228605B (zh) 2013-03-14 2022-08-12 加利福尼亚大学董事会 硫代糖粘液溶解剂
JP6596421B2 (ja) 2013-08-23 2019-10-23 パリオン・サイエンシィズ・インコーポレーテッド ジチオール粘液溶解薬
MX387071B (es) 2015-01-30 2025-03-19 Parion Sciences Inc Agentes mucolíticos de monotiol novedosos
JP2018520986A (ja) 2015-04-30 2018-08-02 パリオン・サイエンシィズ・インコーポレーテッド ジチオール粘液溶解剤の新規なプロドラッグ
WO2020055916A1 (en) 2018-09-10 2020-03-19 The Regents Of The University Of California Dithiolsaccharide mucolytic agents and uses thereof
EP3797783A1 (en) 2019-09-27 2021-03-31 Freie Universität Berlin Novel medical uses of thiol-functionalized polyglycerol derivatives
CN112758902B (zh) * 2021-01-06 2022-01-28 西南科技大学 用于高效析氧反应的优化电子构型Co4N纳米片的制备方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639635A (en) 1969-02-11 1972-02-01 Riker Laboratories Inc Process for the liquefaction of mucus
US3663690A (en) 1969-08-12 1972-05-16 Hoechst Co American Mucolytic composition and method of treatment of broncho-pulmonary disorders therewith
FR2155776B1 (es) * 1971-10-04 1974-11-15 Rech Pharmaceut Scient
BE789811A (fr) * 1971-10-07 1973-04-06 Bristol Myers Co 1,4-bis-acylpiperazines
FR2434149A1 (fr) 1978-06-22 1980-03-21 Parcor Nouveaux derives de la l-cysteine
JPH01226866A (ja) * 1988-03-08 1989-09-11 Wako Pure Chem Ind Ltd メルカプトメチル化方法
FR2685323B1 (fr) * 1991-12-19 1994-04-08 Rhone Poulenc Chimie Mercaptomethylbenzylamines et leur utilisation dans la synthese de bisphenols.
US20010037037A1 (en) 1995-10-31 2001-11-01 Kurt Dietliker Oximesulfonic acid esters and the use thereof as latent sulfonic acids
JP2002012583A (ja) * 2000-04-28 2002-01-15 Sumitomo Chem Co Ltd アミン誘導体の製造方法
US6858614B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
EP1572086A4 (en) 2002-03-06 2008-07-02 Univ Duke METHOD AND COMPOSITION BASED ON THE DISCOVERY OF THE METABOLISM OF NITROGLYCERINE
AU2003226603A1 (en) 2002-04-19 2003-11-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
US7132425B2 (en) * 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
JP4805824B2 (ja) 2003-08-18 2011-11-02 パリオン・サイエンシィズ・インコーポレーテッド キャップ化ピラジノイルグアニジンナトリウムチャネルブロッカー
KR20060037450A (ko) 2003-08-18 2006-05-03 패리온 사이언스 인코퍼레이티드 사이클릭 피라지노일구아니딘 나트륨 채널 차단제
US20050090505A1 (en) 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
AU2004271945A1 (en) 2003-08-18 2005-03-24 Parion Sciences, Inc. Aliphatic pyrazinoylguanidine sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US20090253714A1 (en) 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
US20050059639A1 (en) 2003-09-11 2005-03-17 Wei Edward T. Ophthalmic compositions and method for treating eye discomfort and pain
WO2005094269A2 (en) 2004-03-24 2005-10-13 National Jewish Medical And Research Center Mucolytic and anti-elastase compounds and methods of use thereof
KR20070059063A (ko) 2004-08-18 2007-06-11 마이클 알 존슨. 지방족 아미드 및 에스테르 피라지노일구아니딘 나트륨채널 차단제
US7399766B2 (en) 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
AU2005277398A1 (en) 2004-08-18 2006-03-02 Michael R. Johnson Cyclic amide and ester pyrazinoylguanidine sodium channel blockers
US20090324724A1 (en) 2004-08-18 2009-12-31 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
US7807834B2 (en) 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
US20090192227A1 (en) 2005-08-24 2009-07-30 Rabindra Tirouvanziam N-Acetylcysteine Compositions and Methods for Treating Acute Exacerbations of Inflammatory Lung Disease
WO2007123793A2 (en) 2006-04-04 2007-11-01 Stc.Unm Swellable particles for drug delivery
JP2009535462A (ja) * 2006-04-27 2009-10-01 インテザイン テクノロジーズ， インコーポレイテッド 化学的に異なる末端基を含むポリ（エチレングリコール）
US8324218B2 (en) 2006-06-09 2012-12-04 Parion Sciences, Inc. Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity
CA2654244A1 (en) 2006-06-09 2007-12-21 Parion Sciences, Inc. Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity
US20110195973A1 (en) 2006-06-09 2011-08-11 Parion Sciences, Inc. Cyclic substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity
BRPI0716884A2 (pt) 2006-09-07 2013-10-15 Parion Sciences Inc Método de intensificação de hidratação mucosal e clearance mucosal através de tratamento com bloqueadores do canal de sódio e osmolitos
TW200819430A (en) 2006-09-07 2008-05-01 Michael R Johnson Enhanced mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
CN101534813A (zh) * 2006-09-07 2009-09-16 帕里昂科学公司 通过使用钠通道阻断剂和渗透调节剂的治疗来增加粘膜水化和粘液清除的方法
US20080131500A1 (en) 2006-12-04 2008-06-05 The Board Of Regents Of The University Of Texas System Methods and compositions for rapid inactivation of proteins
WO2008124496A1 (en) 2007-04-03 2008-10-16 Parion Sciences, Inc. Method of treating acid-sensing ion channel mediated pain, cough, and central nervous system disorders
WO2008124491A1 (en) 2007-04-03 2008-10-16 Parion Sciences, Inc. Pyrazinoylguanidine compounds for use taste modulators
AU2008310734B2 (en) 2007-10-10 2014-06-05 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
WO2009076792A1 (en) 2007-12-19 2009-06-25 Givaudan Sa Cooling compounds
WO2009078782A1 (en) 2007-12-19 2009-06-25 Pharmalundensis Ab Method and means for producing bronchorelaxation
KR101654549B1 (ko) 2008-02-26 2016-09-07 패리온 사이언스 인코퍼레이티드 다중방향족 나트륨 채널 차단제
US20100074881A1 (en) 2008-07-11 2010-03-25 Parion Sciences, Inc. Multiple nebulizer systems
JP2012515164A (ja) 2009-01-09 2012-07-05 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 角膜障害を処置するための治療組成物
EP2210936A1 (en) 2009-01-27 2010-07-28 Curetis AG Processing and analysis of viscous liquid biological samples
EP2428582B1 (en) 2010-09-14 2013-09-04 miacom Diagnostics GmbH Clearance buffer
EP3842074A1 (en) * 2010-09-29 2021-06-30 Philogen S.p.A. Protein-drug conjugates
HUE032851T2 (en) 2011-06-27 2017-11-28 Parion Sciences Inc A chemically and metabolically stable dipeptide having strong sodium channel blocking activity
AR086745A1 (es) * 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
WO2013181232A2 (en) 2012-05-29 2013-12-05 Michael Ross Johnson Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
WO2014036445A2 (en) 2012-08-31 2014-03-06 Johnson Michael R Novel mucolytic agents
CN104812736A (zh) 2012-11-28 2015-07-29 陆岩松 合成的新型抗氧化剂及其用途
JP6392242B2 (ja) 2012-12-17 2018-09-19 パリオン・サイエンシィズ・インコーポレーテッド 粘膜への水分付与が不十分であることが好都合である疾患の治療に有用なクロロ−ピラジンカルボキサミド誘導体
MX2015007797A (es) 2012-12-17 2015-10-05 Parion Sciences Inc Compuestos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil) carbamimidoil) pirazin-2-carboxamida.
JP6596421B2 (ja) 2013-08-23 2019-10-23 パリオン・サイエンシィズ・インコーポレーテッド ジチオール粘液溶解薬
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
CN104078680B (zh) 2014-05-23 2015-09-09 南京中储新能源有限公司 一种碳硫复合正极及二次铝硫电池
US20150376145A1 (en) 2014-06-30 2015-12-31 Parion Sciences, Inc. Stable sodium channel blockers
FR3024801A1 (fr) 2014-08-08 2016-02-12 Commissariat Energie Atomique Materiau d'electrode positive a base d'un materiau carbone specifique fonctionnalise par des composes organiques specifiques
MX387071B (es) * 2015-01-30 2025-03-19 Parion Sciences Inc Agentes mucolíticos de monotiol novedosos
JP2018520986A (ja) 2015-04-30 2018-08-02 パリオン・サイエンシィズ・インコーポレーテッド ジチオール粘液溶解剤の新規なプロドラッグ

Also Published As

Publication number Publication date
JP2021004256A (ja) 2021-01-14
US20190031679A1 (en) 2019-01-31
CA2974210A1 (en) 2016-08-04
CN107614480B (zh) 2020-09-15
CN107614480A (zh) 2018-01-19
SG11201705790SA (en) 2017-08-30
AU2016211440A1 (en) 2017-08-10
JP2018505163A (ja) 2018-02-22
JP6826038B2 (ja) 2021-02-03
KR20170108088A (ko) 2017-09-26
EP3250548A1 (en) 2017-12-06
JP7112464B2 (ja) 2022-08-03
US10968233B2 (en) 2021-04-06
US20160222023A1 (en) 2016-08-04
ZA201705122B (en) 2021-01-27
WO2016123335A1 (en) 2016-08-04
EP3250548A4 (en) 2018-07-11
MX387071B (es) 2025-03-19
IL253501B (en) 2021-01-31
BR112017016067A2 (pt) 2018-04-03
AU2016211440B2 (en) 2020-08-27
IL253501A0 (en) 2017-09-28
US10106551B2 (en) 2018-10-23
CN112321472A (zh) 2021-02-05
HK1247909A1 (zh) 2018-10-05

Similar Documents

Publication Publication Date Title
MX387071B (es) Agentes mucolíticos de monotiol novedosos
CO2017007355A2 (es) Compuestos derivados de pirazincarbozamida y de pirazincarboxilato para el tratamiento de la infección por el virus de hepatitis b
MA52665A (fr) Procédé d'amélioration de l'expression de l'hémoglobine foetale
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
MX2019012815A (es) Proceso para la preparacion de compuestos de 2,3-dihidrotiazolo[3, 2-a]pirimidin-4-io opticamente activo.
JO3466B1 (ar) مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
MX2017002328A (es) Analogos de dioxolano de uridina para el tratamiento del cancer.
PE20171094A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
CR20160337A (es) Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
MX2018000412A (es) Moduladores de diaciglicerol aciltransferasa 2 (dgat2).
UY35381A (es) Pirrolotriazinas como inhibidores del canal del ion potasio
SV2017005381A (es) Compuestos de imidazopiridazina
BR112018016883A2 (pt) métodos para fabricação de enxofre polimérico e de um composto de enxofre polimérico.
MX375438B (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
MX2017005044A (es) Activador de canales de kcnq2-5.
LT3484863T (lt) Cikliniai amidai, kaip kalio kanalų atvėrimo agentai
UY37932A (es) Proceso para producir compuestos de piridazinona herbicidas
DOP2016000211A (es) Pirazinas moduladoras de gpr6
BR112017019850A2 (pt) ?processo melhorado para a preparação de apremilast?
BR112019003130A2 (pt) agonista de ppargama para tratamento de cânceres de sangue
ME03673B (me) Proizvodnja 4,5,6,7-etrahidroizozaksolo[5,4-c]piridin-3-ola
EP3447042A4 (en) PRODUCTION PROCESS OF 1,2-DICHLOROHEXAFLUORCYCLOPENTEN
BR112017020408A2 (pt) ?biotinas e composições?
MX2019011517A (es) Proceso para producir analogos de anillo de arilomicina.